Goldman Sachs Group Inc Vaxxinity, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 14, 2024
BUY
$1.43 - $4.24 $136,672 - $405,238
95,575 New
95,575 $216,000
Q1 2023

May 11, 2023
BUY
$1.43 - $4.24 $136,672 - $405,238
95,575 New
95,575 $216,000
Q2 2022

Aug 15, 2022
SELL
$1.55 - $6.95 $150,456 - $674,629
-97,069 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$3.7 - $8.6 $458,914 - $1.07 Million
-124,031 Reduced 56.1%
97,069 $417,000
Q4 2021

Feb 14, 2022
BUY
$5.55 - $18.46 $1.23 Million - $4.08 Million
221,100 New
221,100 $1.24 Million

Others Institutions Holding VAXX

# of Institutions
2
Shares Held
198K
Call Options Held
0
Put Options Held
0
View Full List

About Vaxxinity, Inc.

VAXX Quotes by TradingView
  • Ticker VAXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 112,150,000
  • Description
  • Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...
More about VAXX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email